Welcome to our dedicated page for Apogee Therapeutics SEC filings (Ticker: APGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apogee Therapeutics, Inc. filings document a clinical-stage biotechnology issuer focused on antibody programs for inflammatory and immunology indications. The company’s Form 8-K disclosures cover operating results, Regulation FD clinical-data presentations for zumilokibart (APG777), APG279 and APG333 development activity, and material agreements related to public common-stock offerings.
Proxy materials cover annual meeting matters, director elections, board composition, executive compensation, equity awards and shareholder voting. The filings also identify APGE common stock on The Nasdaq Global Market and provide recurring capital-structure, governance, clinical or regulatory, and financial disclosures tied to the company’s research and development model.
Apogee Therapeutics, Inc. (APGE) reported an insider stock sale by its Chief Financial Officer, who is a reporting officer of the company. On 11/14/2025, the officer sold 2,000 shares of common stock at a price of $65 per share, in a transaction coded as an "S" sale. After this transaction, the officer beneficially owned 197,871 shares of Apogee common stock in direct ownership form. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that was adopted on September 27, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
Apogee Therapeutics (APGE) reported an insider transaction by its Chief Financial Officer, Jane Pritchett Henderson. On 11/11/2025, she sold 1,000 shares of common stock at $60 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 27, 2024. Following the sale, she beneficially owns 199,871 shares, held directly.
Apogee Therapeutics (APGE) filed a Form 4 reporting insider sales by CEO and director Michael Henderson. On 11/13/2025, he sold a total of 20,000 shares in four transactions executed under a Rule 10b5-1 trading plan adopted on August 13, 2025.
Weighted average prices were $61.93 (range $61.45–$62.39), $63.14 (range $62.50–$63.47), $63.89 (range $63.52–$64.39), and $64.52. Following these sales, Henderson directly beneficially owns 1,272,987 shares.
Apogee Therapeutics (APGE) filed its Q3 2025 report, showing a net loss of $65.0 million, driven by operating expenses of $71.3 million. Research and development was $54.2 million and general and administrative was $17.1 million. Interest income contributed $6.3 million.
Liquidity remained strong with cash and cash equivalents of $107.9 million, marketable securities of $419.4 million, and long-term marketable securities of $61.6 million as of September 30, 2025. The company recorded stockholders’ equity of $586.3 million and an accumulated deficit of $492.4 million. Management states these resources will fund operations for at least the next 12 months. Capital actions included $19.4 million of net proceeds from the at-the-market program in Q3 and, subsequently, approximately $324.1 million of net proceeds from an October 2025 underwritten offering of common stock and pre-funded warrants. As of November 3, 2025, shares outstanding were 68,320,229, including 54,833,587 voting and 13,486,642 non-voting shares.
Apogee Therapeutics (APGE) filed its Q3 2025 report, showing a net loss of $65.0 million, driven by operating expenses of $71.3 million. Research and development was $54.2 million and general and administrative was $17.1 million. Interest income contributed $6.3 million.
Liquidity remained strong with cash and cash equivalents of $107.9 million, marketable securities of $419.4 million, and long-term marketable securities of $61.6 million as of September 30, 2025. The company recorded stockholders’ equity of $586.3 million and an accumulated deficit of $492.4 million. Management states these resources will fund operations for at least the next 12 months. Capital actions included $19.4 million of net proceeds from the at-the-market program in Q3 and, subsequently, approximately $324.1 million of net proceeds from an October 2025 underwritten offering of common stock and pre-funded warrants. As of November 3, 2025, shares outstanding were 68,320,229, including 54,833,587 voting and 13,486,642 non-voting shares.
Apogee Therapeutics (APGE) furnished an 8‑K noting two updates. The company issued an earnings press release covering the quarter ended September 30, 2025, and separately announced positive interim Phase 1 results from a healthy volunteer trial of APG333.
The earnings release is furnished as Exhibit 99.1 and the clinical data release as Exhibit 99.2. Both exhibits are furnished, not filed, under the Exchange Act.
Apogee Therapeutics (APGE) furnished an 8‑K noting two updates. The company issued an earnings press release covering the quarter ended September 30, 2025, and separately announced positive interim Phase 1 results from a healthy volunteer trial of APG333.
The earnings release is furnished as Exhibit 99.1 and the clinical data release as Exhibit 99.2. Both exhibits are furnished, not filed, under the Exchange Act.
Apogee Therapeutics (APGE) reported insider activity by its Chief Medical Officer on 11/05/2025. The officer exercised 8,060 stock options at $22.86 and sold common shares in multiple open‑market transactions: 2,300 at $53.62, 2,200 at $54.83, 5,607 at $55.58, and 678 at $56.51.
Following these trades, the officer directly owned 282,008 common shares and held 153,565 derivative securities (options). The filing notes the sales were executed under a Rule 10b5‑1 trading plan adopted on August 21, 2024, with several prices reported as weighted averages across multiple executions.
Apogee Therapeutics (APGE) director Nimish Shah reported acquiring 365,853 pre-funded warrants on 10/10/2025 at $40.9999 per warrant. The warrants are immediately exercisable at $0.00001 per share and have no expiration, subject to a 4.99% beneficial ownership limit. The securities are held by Venrock Opportunities Fund; Shah reports indirect ownership and disclaims beneficial ownership beyond his indirect pecuniary interest.
Apogee Therapeutics, Inc. entered into an underwriting agreement to sell 6,951,221 shares of common stock at $41.00 per share and pre-funded warrants for 365,853 shares at $40.99999 per warrant in a public offering. The company also granted underwriters a 30-day option to buy up to 1,097,561 additional common shares, which was exercised in full, and expects net proceeds of approximately $323.3 million after fees and expenses. The securities are being issued off an effective shelf registration, with closing expected on October 10, 2025. Apogee also updated clinical timelines, now planning to enroll 320 patients and complete enrollment in Part B of its APEX Phase 2 APG777 atopic dermatitis trial by year-end, with topline maintenance data from Part A expected in the first quarter of 2026, Part B 16-week induction data in the second quarter of 2026, and Phase 1b APG777 asthma topline data in the first quarter of 2026.
Apogee Therapeutics, Inc. is offering 6,951,221 shares of voting common stock and, in lieu of shares to certain investors, 365,853 pre-funded warrants at a public offering price of $41.00 per share (pre-funded warrants priced at $40.99999). The company estimates net proceeds of approximately $281.0M, or about $323.3M if the underwriters fully exercise a 30-day option to purchase an additional 1,097,561 shares. Proceeds are intended to fund preclinical and clinical development, manufacturing, commercial readiness and general corporate purposes, and together with existing cash are expected to fund operations into the first half of 2028. Recent clinical updates include an increased Part B enrollment target of 320 patients for the APEX Phase 2 APG777 atopic dermatitis trial, with Part A topline maintenance data expected in Q1 2026 and Part B 16-week induction topline data expected in Q2 2026, and Phase 1b asthma topline data expected in Q1 2026. The pre-funded warrants will not be listed and have limited liquidity; holders have no stockholder rights until exercise.
Apogee Therapeutics, Inc. is offering shares of its voting common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.00001 per share. The company’s common stock trades on Nasdaq under the symbol APGE and had a last reported sale price of $39.73 on October 7, 2025. Apogee is a clinical-stage biotech focused on antibody programs for inflammatory and immunology indications, including atopic dermatitis and asthma.
Recent updates increase the planned Part B enrollment in the APEX Phase 2 trial of APG777 to 320 patients, with Part A maintenance topline data expected in Q1 2026, Part B 16-week induction topline in Q2 2026, and Phase 1b asthma topline in Q1 2026. The prospectus discloses pro forma historical net tangible book value of $619.4M ($10.39 per share as of June 30, 2025) and warns of dilution, limited liquidity for pre-funded warrants, and the need for additional capital to reach regulatory approval and commercialization.
Apogee Therapeutics, Inc. is offering shares of its voting common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.00001 per share. The company’s common stock trades on Nasdaq under the symbol APGE and had a last reported sale price of $39.73 on October 7, 2025. Apogee is a clinical-stage biotech focused on antibody programs for inflammatory and immunology indications, including atopic dermatitis and asthma.
Recent updates increase the planned Part B enrollment in the APEX Phase 2 trial of APG777 to 320 patients, with Part A maintenance topline data expected in Q1 2026, Part B 16-week induction topline in Q2 2026, and Phase 1b asthma topline in Q1 2026. The prospectus discloses pro forma historical net tangible book value of $619.4M ($10.39 per share as of June 30, 2025) and warns of dilution, limited liquidity for pre-funded warrants, and the need for additional capital to reach regulatory approval and commercialization.